Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "ENT"

9304 News Found

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
Drug Approval | November 23, 2025

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy


ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market
R&D | November 23, 2025

ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market

The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules


Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs
R&D | November 21, 2025

Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs

Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure


Mankind Pharma inks licencing pact with Actimed to bring cachexia treatments to South Asia
News | November 21, 2025

Mankind Pharma inks licencing pact with Actimed to bring cachexia treatments to South Asia

The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands


Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Clinical Trials | November 21, 2025

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial

Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration


AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
Drug Approval | November 21, 2025

AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients

The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study


Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
Drug Approval | November 21, 2025

Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment

This is the first and only subcutaneous immune checkpoint inhibitor available in Europe


Cardiol Therapeutics wins US patent protection for heart-disease drug platform
News | November 19, 2025

Cardiol Therapeutics wins US patent protection for heart-disease drug platform

The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38